Response to SARS-CoV-2 initial series and additional dose vaccine in pediatric patients with predominantly antibody deficiency

Data regarding response to SARS-CoV-2 immunization in pediatric patients with predominantly antibody deficiency (PAD) is limited. We evaluated SARS-CoV-2 immunization response by anti-SARS-CoV-2-spike antibody level in 15 pediatric PAD patients. These data were compared to a published cohort of adul...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in immunology 2023-07, Vol.14, p.1217718-1217718
Main Authors: Tandon, Megha, DiGiacomo, Daniel V, Zhou, Baijun, Hesterberg, Paul, Rosenberg, Chen E, Barmettler, Sara, Farmer, Jocelyn R
Format: Article
Language:English
Subjects:
Adult
Antibodies, Viral
Child
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
Humans
Immunology
inborn error of immunity
predominantly antibody deficiency
primary immune deficiency
Primary Immunodeficiency Diseases
SARS-CoV-2
Vaccination
vaccine
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Data regarding response to SARS-CoV-2 immunization in pediatric patients with predominantly antibody deficiency (PAD) is limited. We evaluated SARS-CoV-2 immunization response by anti-SARS-CoV-2-spike antibody level in 15 pediatric PAD patients. These data were compared to a published cohort of adult PAD patients (n=62) previously analyzed following SARS-CoV-2 immunization at our single center institution. We evaluated demographics, clinical characteristics, immunophenotype, infection history, and past medication use by chart review. Following a two-dose monovalent initial series SARS-CoV-2 immunization, mean anti-SARS-CoV-2-spike antibody levels were significantly higher in pediatric PAD patients compared to adult PAD patients (2,890.7 vs. 140.1 U/mL; p
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2023.1217718